NCT01581710View on ClinicalTrials.gov

Response of FeNO, Small Airway Dysfunction and Lung Heterogeneity to 2-week Montelukast Treatment in Asthmatic Children.

NACompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

December 31, 2015

Conditions
Mild Persistent Asthma
Interventions
DRUG

Montelukast to placebo

Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks

DRUG

Placebo to montelukast

Subjects will receive matching placebo. Each treatment period consists of 2 weeks

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

CHA University

OTHER

NCT01581710 - Response of FeNO, Small Airway Dysfunction and Lung Heterogeneity to 2-week Montelukast Treatment in Asthmatic Children. | Biotech Hunter | Biotech Hunter